Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04278781 | AG-120 in People With IDH1 Mutant Chondrosarcoma | PHASE2 | ACTIVE NOT_RECRUITING | 6 | — | — | Mar 4, 2020 | Mar 1, 2027 | Apr 23, 2026 | 5 | United States |
Progression free survival includes both disease progression (as defined by RECIST 1.1) and death from any cause
| Arm | Type | Description |
|---|---|---|
| Chondrosarcoma | EXPERIMENTAL | Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma |
| Name | Type | Description |
|---|---|---|
| AG-120 | DRUG | AG-120 500 mg orally once daily days 1-28 of a 28-day cycle |
Inclusion Criteria: * Be \>/= 18 years of age * Have a histological diagnosis (fresh or archived tumor biopsy sample) of locally advanced/metastatic or recurrent operable chondrosarcoma (conventional grade 2 or 3 only) confirmed by central pathology review * Patients with low grade (grade 1) and...